NCT00097513已完成不适用
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or greater)
- •Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater
- •Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk
- •Ability to keep follow-up appointments throughout the study
- •Willingness to remain on therapy until epiphyseal closure is achieved
- •Prior enrollment in NCGS Core Study 85-036
排除标准
- •Treatment with non-Genentech GH preparation
- •Closed epiphyses
- •Active neoplasia
- •Treatment with insulin for diabetes
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)Chronic Renal InsufficiencyEnd-Stage Renal DiseaseNCT00097617Genentech, Inc.395
已完成
不适用
National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and ProtropinGrowth DisordersNCT00097539Genentech, Inc.65,205
已完成
不适用
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth DisordersGrowth Hormone DisordersNCT00455728Ipsen3,690
已完成
不适用
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B StudyHepatitis B, ChronicNCT02201407Hoffmann-La Roche50
已完成
不适用
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet ComponentsTransfusion Related Acute Lung InjuryNCT02549222Cerus Corporation2,291